Ars Pharmaceuticals
ARS Pharmaceuticals Inc is an American commercial-stage biopharmaceutical enterprise specializing in the research, development, and commercialization of innovative, user-friendly pharmaceutical products for severe allergic reactions, prominently featuring neffy (an intranasal epinephrine spray designed as a needle-free alternative to traditional epinephrine auto-injectors for the emergency treatment of severe allergic reactions and anaphylaxis). The company conducts advanced clinical trials and commercial distribution operations supplying emergency allergy therapeutics to patients, allergists, and healthcare providers. Its core business operations encompass biopharmaceutical research, intranasal drug delivery engineering, FDA regulatory navigation, and commercial pharmaceutical sales. Revenue is derived primarily from the commercial prescription sales of neffy in pharmaceutical markets. ARS Pharmaceuticals holds a leading market position in needle-free emergency allergy therapeutics and anaphylaxis treatments. The company is headquartered in San Diego, California, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker SPRY.
2 of the funds FundTelligence covers report a position in Ars Pharmaceuticals.
- Legal name
- ARS PHARMACEUTICALS INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Ars Pharmaceuticals
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)